

Treatment with radiosynoviorthesis in hemophilic patients with and without inhibitor

Mario Edgar Tena Sanabria (✉ dulce.bustamante@permanyer.com)

Hospital de Especialidades Centro Medico Nacional Siglo XXI <https://orcid.org/0000-0002-0593-4588>

Y. Rojas Sato

Hospital de Especialidades Centro Medico Nacional Siglo XXI

J.C Castañeda Resendiz

Hospital de Especialidades Centro Medico Nacional Siglo XXI

G. Fuentes Herrera

Hospital de Especialidades Centro Medico Nacional Siglo XXI

Yureni Irani Tena González

Hospital de Especialidades Centro Medico Nacional Siglo XXI

Juan Carlos Núñez Enríquez Ne

Hospital de Especialidades Centro Medico Nacional Siglo XXI

Félix Alejandro Álvarez Martínez Ne

Hospital de Especialidades Centro Medico Nacional Siglo XXI

Research article

Keywords: Hemophilia, Hemarthrosis, Hemophilic arthropaty, Radiosynoviorthesis

Posted Date: March 4th, 2020

DOI: <https://doi.org/10.21203/rs.2.15342/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Pediatrics on April 20th, 2020. See the published version at <https://doi.org/10.1186/s12887-020-02071-3>.

Abstract

Background. Spontaneous bleedings occurring into joints (hemarthrosis) are the most common manifestations of hemophilia and causes severe joint damage ultimately resulting in joint dysfunction known as hemophilic arthropathy. Among available therapeutic options for reducing recurrent hemarthrosis-associated damage, radiosynoviorthesis (RS) has proven effective in improving joint function.

Aim. To assess the impact of RS with Yttrium(90) citrate (C-Y(90)) on frequency of hemarthroses, need for prophylaxis and joint function in a group of pediatric patients.

Methods. Between November 1998 and February 2017, we evaluated 27 pediatric patients with mild, moderate or severe hemophilia with haemophilic arthropathy. Overall, RS was applied in 60 joints. Some patients received more than one single intra-articular injection with C-Y(90).

Results. During the follow-up, one patient showed joint bleeding 15 months after RS, one patient after 12 months and one patient after 45 days. The need for prophylaxis was reduced and joint function significantly improved in all patients. **Conclusion.** RS with C-Y(90) is a simple and safe treatment for reducing the frequency of hemarthroses in patients with hemophilia. It decreases the use of factor VIII / IX and improves joint function.

Background

Haemophilia A and B are X-linked coagulation disorders caused by the deficiency of factor VIII (FVIII) and factor IX (FIX), respectively. Almost one-third of hemophilic patients will develop inhibitors against FVIII / FIX during replacement therapy (more common in hemophilia A than in B), which increases the difficulty in treatment [1].

Haemophilia A affects 1 in 10,000 male live births, while hemophilia B affects 1 in 30,000 or more [1,2]. In Mexico, the exact figure is unknown because there is still no a reliable national registry that allows us an accurate epidemiological diagnosis.

Spontaneous bleedings occurring into joints (hemarthrosis) are the most common manifestations of hemophilia, accounting for 65-80% of all bleedings in patients with severe hemophilia [3,4]. Although any joint may be affected, the most frequent joints affected are, in descending order, knees, elbows, ankles, hips and shoulders. Recurrent bleeding from the synovial vessels into the intra-articular space facilitates iron deposits, which trigger a cytokyne-mediated inflammatory and oxidative reaction, resulting in vascular proliferation. This vicious circle promotes synovial hypertrophy and predisposes to repetitive hemarthrosis in the same joint (target joint), which eventually lead to the functional disability known as hemophilic arthropathy [4-8].

In addition to its impact on the patient's functional capacity, hemophilic arthropathy increases costs of hospitalization due to the time that patients must remain hospitalized, both during acute exacerbations and subsequent rehabilitation necessary to return to their normal daily activities.

Hematologic prophylaxis is recommended as mechanism to prevent bleedings and preserve musculoskeletal function. Haemophilic arthropathy can be prevented by giving regular prophylaxis and implementing physiotherapy programme, [4] but if chronic synovitis is already evident, despite the use of prophylaxis, it should be treated with chemical or radioisotope synoviorthesis [4,9], with surgical procedures being restricted to non-responding patients to previous strategies.

The term synoviorthesis (medical synovectomy) is commonly used to describe the intra-articular procedures aimed to produce destruction/ fibrosis of the synovial membrane and subsynovial plexus.

Radiosynoviorthesis (RS) is a therapeutic modality based on the intra-articular injection of a colloidal suspension of radioisotope-labeled particles aimed to the restoration (orthesis) of the synovium.

Historically, this procedure has been performed with Yttrium(90) citrate (C-Y(90)), phosphor 32 (32P), gold 138 (138Au), rhenium 138 (138 Re) or erbium 169 (169 Er). New radioisotopes have now been developed, such as samarium 153 (153 Sm) and holmium 166 (166 Ho), which have shown similarly effective results for patients with chronic synovitis [4,9].

The aim of our study was evaluating the efficacy of RS with C-Y(90) on joints with recurrent hemarthroses in pediatric patients with mild, moderate or severe hemophilia with and without inhibitor.

In particular, we tried to quantify the hemarthroses-free time and joint function improvement after the use of RS with C-Y(90) and to determine whether the use of factor VII, VIII and IX decreased in the emergency department.

Methods

Patients with severe hemophilia treated with RS using C-Y(90) during November 1998 to February 2017 at the Department of Orthopedics of the Pediatric Hospital, National Medical Center Siglo XXI, IMSS were enrolled in the present study.

The variables collected included place of birth; age at the time of the first C-Y(90) application, weight and height; degree and stage of haemophilic arthropathy. The response of the joint after application of C-Y(90), the number of hemarthroses per month, the number of doses of factor VIII, IX, and factor VII for patients with inhibitor, number of joints treated, number of patients with inhibitor, joint bleeding-free time and function were also recorded.

To classify the hemophilic arthropathy at each time of C-Y(90) application we used Pettersson score. This is based on typical findings of hemophilic arthropathy on posterior-anterior and lateral X-rays, including osteoporosis, enlargement of epiphysis, irregularity of subchondral surface, narrowing of joint

space, subchondral cysts, erosions at joint margins, incongruence between joint surfaces, and the angulation and/or displacement of articulating bone ends. The maximum Pettersson score joint is 13 points indicating more joint damage [10].

The decision to use RS was based on the clinical status of patients at the moment of admission to our department which had been referred from second-level hospitals. None of the patients had received prophylactic treatment and presented recurrent joint bleedings (two or more joint bleeds in one month). They presented signs of progressive arthropathy (being no greater than grade III, according to the Arnold and Hilgartner classification), increased joint size, pain and limited mobility arches.

For the RS, different radioisotopes can be used. The selection of the radioisotope should take into account two parameters [4,11]: 1) physical properties: half-life, soft tissue penetration, size of the radiocolloid, 2) and clinical features: joint size, amount of joint fluid, synovial thickness. The material should also be a pure beta emitter, thereby minimizing the whole body exposure to gamma radiation [4, 8,12,13].

Among the available radioisotopes, we chose C-Y(90) taking into account their physical properties and clinical characteristics, as well as the good results obtained with RS with this medication published in the literature in pediatric patients.

All patients received replacement therapy to cover the procedure with FVIII and FIX except those with inhibitor. Of the group with inhibitor (n=6): one patient received activated recombinant FVII, while the others received FEIBA (mainly non-activated factors II, IX and X, as well as activated factor VII)".

After the application of C-Y(90), a cotton bandage (called Jones' bandage) was placed for three days, and rest with limb elevation at home was indicated; ambulation was allowed in those who presented hemophilia type A and B without inhibitor. The response to the procedure was evaluated by the presence / absence of bleeding of the treated joint, with monthly assessment, and then every three and six months during the follow-up time before being discharged from the Pediatric Unit.

Patients with inhibitor were admitted to the hospital for two or three days to administer the necessary medication and to control bleeding. Depending on the affected joint, the procedure, type of hemophilia, and its severity, substitution therapy was maintained.

Results

During the study period, RS with C-Y(90) was applied in 60 joints of 27 patients: 29 knees, 21 ankles, and 10 elbows. The patients were between 3 and 16 years old at the time of the first RS procedure. They suffered between two and five episodes of hemarthrosis per month (12 per year in average) before C-Y(90) application. 22 had hemophilia A and 5 had hemophilia B. In the group with severe hemophilia A, five were patients with inhibitor (Table 1). Before RS treatment initiation and follow-up period none of the patients received prophylaxis.

The patients were followed in our center while they were pediatric (median 9.5 months). When they reached the age of 16 years and 11 months they were referred to be treated in adult units. The younger patients included in our study are currently under surveillance.

During the follow-up period, one patient showed a joint bleeding 15 months after RS, one patient after 12 months and one patient after 45 days. At that moment, a new intra-articular injection with C-Y(90) was performed in these patients. The remaining patients had no new hemarthrosis during the follow-up period. As patients did not present hemarthrosis, they recovered their mobility arches that were previously limited by joint bleedings (Figure 1).

Four patients with inhibitor showed high response with previous administration of FVIIrA, suggesting that the presence of inhibitor does not prevent RS from being effective.

Discussion

Among complications associated with hemophilia, joint bleeding (hemarthrosis) and subsequent chronic synovitis are the most prevalent, accounting for 65% to 80% of all bleedings in patients with severe hemophilia. [1] Synovitis results from the presence of iron in the joint space that, when interacting with synoviocytes, stimulates the expression of the c-myc and MDM2 proto-oncogenes. These proto-oncogenes allow proliferation of synovial cells and block the apoptotic signaling cascade, ultimately provoking synovial hyperplasia. Simultaneously, macrophages and monocytes migrate to the joint, with secretion of vascular endothelial growth factor, interleukin 1 alpha, interleukin 6 and tumor necrosis factor alpha. These factors are responsible for stimulating osteoclasts, fibroblasts and T cells to produce substances that will promote the proliferation of blood vessels in the synovium and proinflammatory substances that will induce damage to the cartilage and its subsequent degeneration [14-16].

Synovial hyperplasia is characterized by a rich vasculature and fragility for ruptures due to mild trauma. This will produce a new hemarthrosis that will perpetuate the damage and degeneration of the joint.

Hematologic prophylaxis is recommended as a mechanism for preventing bleedings and preserving normal musculoskeletal function in patients with hemophilia. However, if chronic synovitis is already present, despite the use of prophylaxis, synoviorthesis, whether chemical or with radionuclides, should be used [4,9].

The RS was first described by Fellingner Schmid in 1952 as a therapeutic strategy in chronic synovitis, but Ahlberg was the first to use radionuclides for fibrous synovium in patients with hemophilia in 1971 [6].

This procedure should be performed after the finding of radiological signs of chronic arthropathy, as well as in grades I-II according the classification proposed by Fernández-Palazzi [4].

Radiographic studies show that, at the tissue level, colloidal suspension is phagocytosed by the macrophages in the superficial layer of the synovial membrane, achieving, with selective irradiation, initial hyperemia and increased leukocyte migration, with subsequent increase of the cellular and humoral

defense reaction. The final consequence is a reduction of inflammation. Later, at two or three months, sclerosis and fibrosis of the synovial membrane can be observed [17].

RS in children is a controversial therapeutic procedure due to the use of radioactive isotopes. However, in line with our results, several studies have shown an excellent response to RS in children with hemophilia, and a good safety profile.

Research by Rodríguez-Merchán et al. in the hemophilia center of the Hospital de la Paz in Madrid, Spain, showed an improvement in joint function in young patients treated with RS in whom synovial membranes were not yet severely injured [18]. Heim et al. reported that RS in hemophiliac patients with chronic synovitis provides an 80% decrease in hemarthrosis and that 15% of cases did not present new episodes [19]. Manco-Johnson et al. in a study with 91 joints of 59 children with hemophilia with and without inhibitors of coagulation factors VIII and IX, found that RS limited the frequency of hemarthrosis, decreased pain, and improved joint function [20]. Kavakli et al in a series of 221 RS in 150 children and young adults reported a reduction of hemarthrosis in all patients, especially those with grade II synovitis and with early experience with 90Y [21]. Alioglu et al evidenced that RS was the best therapeutic procedure to halt the evolution of chronic hemophilic synovitis into hemophilic arthropathy in 18 patients with a mean age of 12 years and severe hemophilia with grade I or II synovitis [22]. Also Turkmen et al. in their study on the use of RS with Y-90 on 82 knees of 67 pediatric patients and young adults with synovitis secondary to hemophilia showed that it was possible to delay the progression of arthropathy and increase the time to re-bleeding [23]. Martínez-Esteve et al. in their series of 20 children and adolescents with hemophilia (mean age 13 years) reported that in the 70.3% of the joints the RS had a good or excellent response and in 29.7% a partial response [24].

The efficacy of RS ranges between 76% and 80%, and the percentage of failure of the procedure in the control of hemarthrosis is considered to be 20%. When compared with chemical synoviorthesis, authors such as Bessant et al. report a variable and changing response throughout the months of evolution, with efficacy being 67% at six months and 50% at twelve months [25].

Complications are rare if the technique is performed properly. General complications include fever or allergy to the radiotracer (very rare), and local complications, related to joint puncture, include local pain, septic arthritis or lymphedema. Cutaneous necrosis with fistulization through the needle path is very rare. There is a risk of acute synovitis after treatment, although this possibility decreases when corticosteroids are associated [16]. Premalignant lesions or changes in the structure of chromosomes have not been demonstrated in patients who have been given 90Y and 186 Re [16,26]. In the present study, neither adverse effects or complications associated with RS using C-Y(90) were observed.

The effectiveness of RS, the decreased number of procedures required for controlling hemarthrosis, the improvement in joint mobility and the lower amount of prophylaxis required are parameters that all together have led to recommend RS as the procedure of choice in patients with haemophilic arthropathy [16].

It has been mentioned that RS presents a number of advantages such as: simplicity, safety, shorter or unnecessary hospitalization, limited cost, as well as the possibility of repeating the technique without loss of efficacy and performing posterior surgical synovectomy, if necessary [19-24,27]. In the present research, need for prophylaxis was reduced in all patients treated with RS. Emergency service use was also reduced. Presumably, but not evaluated in the present investigation, costs of hospitalization were reduced in all patients both during acute joint bleedings and subsequent rehabilitation therapy necessary to return to their normal daily activities, including school attendance.

Conclusion

Radiosynoviorthesis with C-Y(90) may be the ideal treatment for recurrent hemarthrosis in patients with hemophilia, considering that it reduces inflammation and, later on (two to three months), causes sclerosis and fibrosis of the synovial membrane, thus avoiding new episodes of hemarthrosis .

In hemophilic arthropathy, the effectiveness of RS is reflected in the decrease in the number of procedures required to control hemarthrosis. It is used in a single application, the procedure is simple, safe, of limited cost, and can be repeated if necessary. It does not require hospital admission, it has an improvement in joint mobility and a decrease in the use of factor VIII / IX, it does not cause adverse reactions such as sarcomas or leukemias, and represents a significant saving for the institution. In our opinion, these advantages lead to the recommendation of radiosynoviorthesis as the procedure of choice in patients with hemophilic arthropathy.

Declarations

Ethics approval and consent to participate

Written consent to participate was obtained from the parents of patients. Additionally, written assent was obtained from those participants older than 8 years of age. This decision was supported and approved by the Local Committee of Bioethics and Research of the Pediatrics Hospital National Medical Center "Siglo XXI".

Consent for publication

This is an original work, neither published, accepted or submitted for publication elsewhere. If the article is accepted, we transfer the copyright to the journal.

Availability of data and material

Not applicable.

Competing Interest

The authors declare that there is no conflict of interest.

Funding

Not applicable

Authors' contributions

M.E.T.S., Y.R.S., J.C.C.R., G.F.H., F.A.A.M., Y.I.T.G., and J.C.N.E., participated with the same contribution in the development of this manuscript. Also, all authors have read and approved the manuscript.

Acknowledgements

None.

Abbreviations

(RS)- Radiosynoviorthesis

(C-Y(90))- Yttrium(90) citrate

(32P)- Phosphor 32

(138Au)- Gold 138

(138 Re)- Rhenium 138

(169 Er)- Erbium 169

(153 Sm)- Samarium 153

(166 Ho)- Holmium 166

References

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. *N Engl J Med.* 2001; 344:1773-79.
2. WFH 2015 Annual Global Survey. wfh.org/en/resources/annual-global-survey. Accessed on November 10th.
3. Coppola A, Franchini M. Target of prophylaxis in severe haemophilia: more than factor levels. *Blood Transfus.* 2013 Jul; 11(3): 327-9.
4. Pasta G, Mancuso ME, Perfetto OS, Solimero LP. Radiosynoviorthesis in children with haemophilia. *Hämostaseologie* 2009; 29 (Suppl.1): S62-S64.
5. Aronstam A, Rainsford SG, Painter MJ. Patterns of bleeding in adolescents with severe haemophilia A. *BMJ* 1979; 1: 469-70.

6. Fernandez-Palazzi F. Treatment of acute and chronic synovitis by non-surgical means. *Haemophilia* 1998; 4: 518-23.
7. Chrapko B, Zwolak R, Nocuń A, Gołębowska R, Majdan M. Radiation synovectomy with ⁹⁰Y colloid in the therapy of recurrent knee joint effusions in patient with inflammatory joint diseases. *Rheumatol Int* 2007; 27:729-34.
8. Rodriguez-Merchan EC, Goddard NJ. The technique of synoviorthesis. *Haemophilia*. 2001; 7 (Suppl 2):11-5.
9. Heim M, Horoszowski H, Lieberman L, Varon D, Martino-witz U. Methods and results of radionucleotide synovectomies. In: Gilbert MS, Greene WD, eds. *Musculoskeletal Problems in Hemophilia*. New York: National Hemophilia Foundation, 1990: 98±10.
10. Pettersson H, Ahlberg A, Nilsson IM (1980) A radiologic classification of hemophilic arthropathy. *Clin Orthop Relat Res* 149:153–159
11. Mödder G. *Die Radiosynoviorthese*. Meckenheim, Germany: Warlich Druck und Verlagsgesellschaft mbH; 1995.
12. -Dorenbosch LLJ, de Vet HCW, van der Linden S. Yttrium radiosynoviorthesis en the treatment of knee arthritis in rheumatoid, arthritis:a systematic review. *Ann Rheum Dis* 2000; 59:583-6.
13. Rodriguez Merchan EC, Quintana M. De la Corte Rodriguez. Radioactive synoviorthesis for the treatment of haemophilic sinovitis. *Haemophilia* 2007; 13 (suppl 3): 32-7.
14. Wyseure T, Mosnier LO, von Drygalski A. Advances and Challenges in Hemophilic Arthropathy. *Seminars in hematology*. 2016; 53(1):10-9.
15. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. *J Thromb Haemost*. 2010;8: 1895-902.
16. Schneider P, Farahati J, Reiners C. Radiosynovectomy in Rheumatology, Orthopedics, and Hemophilia. *J Nucl Med* 2005; 46:48S–54S.
17. Özcan Z. Radiosynovectomy in Hemophilic Synovitis. *Molecular Imaging and Radionuclide Therapy*. 2014; 23(1):1-4.
18. Rodriguez-Merchan EC, Caviglia HA, Magallon M, Perez-Blanco R. Chemical synovectomy vs. radioactive synovectomy for the treatment of chronic haemophilic synovitis: a prospective short-term study. *Haemophilia* 1997; 3: 118-22.
19. Heim M., Tiktinsky R., Amit Y, Martinowitz U. Yttrium synoviorthesis of the elbow joints in persons with haemophilia. *Haemophilia*, 2004; 10:590-2.
20. Manco-Johnson MJ, Nuss R, Lear J *et al*. ³²P Radiosynoviorthesis in children with hemophilia. *J Pediatr Hematol Oncol* 2002; 24: 534-9.
21. Kavakli K, Aydogdu S, Taner M. Radioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shoulders. *Haemophilia*. 2008; 14(3): 518-23.
22. Alioglu B, Ozsoy H, Koca G, Sakaogullari A, Selver B, Ozdemir M. The effectiveness of radioisotope synovectomy for chronic synovitis in Turkish paediatric haemophiliacs: Ankara experience.

Haemophilia 2010; 16: 932-6.

23. Turkmen C, Kilicoglu O, Dikici F, Bezgal F, Kuyumcu S, Gorgum O. Survival analysis of Y-90 radiosynovectomy in the treatment of haemophilic synovitis of the knee: A 10-year retrospective review. *Haemophilia* 2014; 20: 45-50.
24. Martínez-Esteve A, Álvarez-Pérez RM, Núñez-Vázquez R *et al.* Sinoviortesis radioisotópica en pacientes en edad pediátrica y adolescentes con hemofilia. *Rev Esp Med Nucl Imagen Mol* 2016; 35:12-6.
25. Bessant R, Steuer A, Rigby S, Gumpel M. Osmic acid revisited: Factors that predict a favourable response. *Rheumatology (Oxford)* 2003; 42: 1036-43.
26. Vuorela J, Sokka T, Pukkala E, Hannonen P. Does yttrium radiosynovectomy increase the risk of cancer in patients with rheumatoid arthritis? *Ann Rheum Dis.* 2003; 62:251–253.
27. Rodriguez-Merchan EC, De la Corte-Rodriguez H, Jimenez-Yuste V. Radiosynovectomy in haemophilia: Long-term results of 500 procedures performed in a 38-year period. *Thrombosis Research* 2014; 134 (5): 985-90.

Tables

Due to technical limitations, all Table(s) are only available as a download in the supplemental files section.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table3.JPG](#)
- [Table2.JPG](#)
- [Table1.JPG](#)